VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ALXO
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ALXOALX Oncology Holdings Inc.
$0.97$131M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksALXOFinancials

ALX Oncology Holdings Inc. (ALXO) Income Statement

8Y historyFree accessUpdated daily

Revenue was absent across the ten quarters shown, with operating losses narrowing from -$41.5M in 2024Q2 to -$18.0M in 2026Q2 primarily because R&D expense fell roughly 62 percent over the period.

Income StatementBalance SheetCash FlowRatios

ALXO Income Statement

Annual statement

ALXO Income Statement

ALX Oncology Holdings Inc. (ALXO) annual income statement — 8-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18
Sales/Revenue0000001.18M4.8M2.07M
Revenue Growth %------100%-75.35%132.03%-
Cost of Goods Sold150K000001.07M4.36M1.88M
COGS % of Revenue------90.95%90.91%90.95%
Gross Profit-150K00000107K436K187K
Gross Margin %------9.05%9.09%9.05%
Gross Profit Growth %------100%-75.46%133.16%-
Operating Expenses82.82M104.02M142.47M170.28M127.44M83.56M43.77M19.62M13.87M
OpEx % of Revenue------3703.05%409.07%671.07%
Selling, General & Admin21.35M23.85M26.09M28.48M29.04M23.39M14.81M3.31M2.6M
SG&A % of Revenue------1252.88%69.08%125.83%
Research & Development61.85M77M116.37M141.79M98.4M60.17M28.96M16.31M11.27M
R&D % of Revenue------2450.17%339.99%545.23%
Other Operating Expenses-388K3.17M0000000
Operating Income-82.97M-104.02M-142.47M-170.28M-127.44M-83.56M-43.66M-19.18M-13.68M
Operating Margin %-------3693.99%-399.98%-662.02%
Operating Income Growth %-26.99%16.33%-33.62%-52.52%-91.36%-127.61%-40.19%-
EBITDA-82.58M-103.31M-141.59M-169.44M-127.09M-83.5M-43.46M-18.75M-13.25M
EBITDA Margin %-------3676.9%-391.03%-641.17%
EBITDA Growth %25.5%27.03%16.43%-33.32%-52.2%-92.14%-131.74%-41.51%-
D&A (Non-Cash Add-back)387K706K872K836K342K51K202K429K431K
EBIT-57.75M-100.09M-133.12M-159.24M-123.18M-83.47M-43.66M-19.19M-13.69M
Net Interest Income2.26M2.36M7.64M9.08M4.04M-12.91K-811K-21K0
Interest Income4.64M3.96M9.37M10.65M4.28M91000
Interest Expense774K1.6M1.73M1.56M238K13K811K21K0
Other Income/Expense2.39M2.33M7.62M9.47M4.02M71K-1.84M-26K-2K
Pretax Income-80.57M-101.69M-134.85M-160.81M-123.42M-83.48M-45.5M-19.21M-13.69M
Pretax Margin %-------3849.32%-400.52%-662.12%
Income Tax000064K-21K241K34K45K
Effective Tax Rate %0%0%0%0%-0.05%0.03%-0.53%-0.18%-0.33%
Net Income-80.57M-101.69M-134.85M-160.81M-123.48M-83.46M-45.74M-19.24M-13.73M
Net Margin %-------3869.71%-401.23%-664.3%
Net Income Growth %25.4%24.59%16.14%-30.23%-47.95%-82.47%-137.7%-40.14%-
Net Income (Continuing)-80.57M-101.69M-134.85M-160.81M-123.48M-83.46M-45.74M-19.24M-13.73M
Discontinued Operations000000000
Minority Interest000000000
EPS (Diluted)-0.57-1.90-2.58-3.74-3.03-2.07-1.28-0.88-0.79
EPS Growth %57.14%26.36%31.02%-23.43%-46.38%-61.72%-45.45%-11.39%-
EPS (Basic)--1.90-2.58-3.74-3.03-2.07-1.28-0.88-0.79
Diluted Shares Outstanding140.9M53.66M52.17M42.99M40.7M40.31M39.84M21.95M21.95M
Basic Shares Outstanding140.9M53.66M52.17M42.99M40.7M40.31M39.84M21.95M21.95M
Dividend Payout Ratio---------

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetMixed
Cash FlowMixed
Top Statement Risk

Persistent operating losses and funding dependence

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Revenue Absent, Losses Narrowing Steadily

Based on ALXO's reported quarterly figures, revenue was essentially absent across the ten quarters shown, with only minimal COGS of $150K and $220K appearing in two periods, so top-line growth cannot be meaningfully measured.

The absence of reported revenue means the growth-rate column is not interpretable, and no conclusion about revenue durability can be drawn from this data. The more informative trend is the compression of operating losses from roughly -$37.8M in 2024Q1 to -$18.0M in 2026Q2, which reflects a shrinking R&D base rather than any commercial traction. Investors should monitor whether future quarters show a revenue line emerging, as the current profile is that of a pre-commercial development-stage entity.

R&D Reduction Drives Expense Discipline

As reported in the income statement, ALXO's R&D expense fell from $34.7M in 2024Q2 to $13.1M in 2026Q2, roughly a 62 percent reduction, representing the dominant driver of the narrowing operating loss.

R&D accounts for the overwhelming majority of operating expenses, while SG&A has held in a relatively narrow band of about $5M to $8M per quarter. The steady R&D decline may suggest program prioritization or pipeline pruning, though the filings alone do not establish which interpretation is correct. Lower spending improves near-term runway arithmetic, but it also warrants scrutiny of whether clinical momentum is being sacrificed.

Stock Compensation Weighs on Reported Losses

Based on ALXO's reported figures, stock-based compensation ran between $2.1M and $7.3M per quarter, a meaningful share of operating expenses that complicates the read on underlying cash burn.

Because net loss roughly tracks operating loss with little non-operating offset, the reported EPS of -$0.13 to -$0.76 per share is largely an operating story rather than a financing or tax artifact. Stock compensation fluctuates considerably across quarters, which means quarter-to-quarter loss comparisons are partly distorted by equity grant timing. Investors may wish to separate SBC from cash expenses when assessing the true economic burn.

Pre-Revenue Model Carries Dilution Risk

The strongest bear case is that ALXO shows no reported revenue against a cumulative operating loss exceeding $200M over ten quarters, implying continued reliance on external capital markets.

The persistent gap between operating expenses and zero commercial revenue suggests the company remains dependent on equity or debt financing to fund development. Share count growth implied by EPS movements and the scale of historical losses may indicate future dilution pressure. Whether the current R&D reduction reflects disciplined capital allocation or a constrained funding position is a question the reported figures alone cannot resolve, and investors should monitor this closely.

ALXO — Frequently Asked Questions

Quick answers to the most common questions about buying ALXO stock.

What was ALX Oncology Holdings Inc.'s (ALXO) revenue in 2025?

For fiscal year 2025, ALX Oncology Holdings Inc. (ALXO) reported total revenue of $0.0M. This represents a 100.0% decline compared to $2.1M in 2018.

Is ALX Oncology Holdings Inc. (ALXO) profitable?

ALX Oncology Holdings Inc. (ALXO) reported a net loss of $101.7M for the fiscal year ending 2025.